STAR-0310 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any prescription or non-prescription medications at least 5 half-lives or 7 days before joining the trial, whichever is longer.
Are You a Good Fit for This Trial?
This trial is for healthy adults who may be interested in helping to test a new drug called STAR-0310. People of Japanese descent might also join an additional group. Participants must meet certain health requirements, but specific inclusion and exclusion criteria are not listed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of STAR-0310 or placebo
Follow-up
Participants are monitored for safety, tolerability, pharmacokinetics, and immunogenicity after treatment
What Are the Treatments Tested in This Trial?
Interventions
- STAR-0310
Find a Clinic Near You
Who Is Running the Clinical Trial?
Astria Therapeutics, Inc.
Lead Sponsor